These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. High-level tissue specific expression of human CD59, MCP, and DAF proteins from genomic clones in transgenic mice. Oldham ER; Velardo MA; Platt JL; Logan JS; Diamond L Transplant Proc; 1996 Apr; 28(2):693. PubMed ID: 8623349 [No Abstract] [Full Text] [Related]
3. Characterization of complement-mediated liver damage and protection in control and transgenic mice for human complement blockers MCP and DAF. Mulder LC; Mora M; Lazzeri M; Boschi M; Ciccopiedi E; Marinucci G; Melli CM; Bruzzone P; Alfani D; Cortesini R; Rossini M Transplant Proc; 1996 Feb; 28(1):127-9. PubMed ID: 8644143 [No Abstract] [Full Text] [Related]
4. Mice transgenic for human CD46 and CD55 are protected from human complement attack. Mulder LC; Mora M; Ciccopiedi E; Melli C; Nuti S; Marinucci G; Bruzzone P; Lazzeri M; Lorenzini R; Alfani D Transplant Proc; 1995 Feb; 27(1):333-5. PubMed ID: 7533403 [No Abstract] [Full Text] [Related]
5. Human MCP and DHF double transgenic mice are protected from human complement attack in an in vivo model. Mulder LC; Mora M; Lazzeri M; Boschi M; Ciccopiedi E; Melli C; Bruzzone P; Alfani D Transplant Proc; 1996 Apr; 28(2):589. PubMed ID: 8623287 [No Abstract] [Full Text] [Related]
6. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion. McCurry KR; Kooyman DL; Diamond LE; Byrne GW; Logan JS; Platt JL Transplantation; 1995 Apr; 59(8):1177-82. PubMed ID: 7537395 [TBL] [Abstract][Full Text] [Related]
7. Difference of expression levels between gene technological product delta CYT-MCP(CD46) and intact MCP(CD46) in transgenic mice. Miyagawa S; Ikawa M; Kominami K; Yoshimura Y; Tanaka H; Mikata S; Shirakura R; Matsuda H; Yanagi Y; Seya T; Okabe M Transplant Proc; 1996 Apr; 28(2):585-6. PubMed ID: 8623285 [No Abstract] [Full Text] [Related]
17. In vitro and in vivo studies to prevent hyperacute rejection. Miyagawa S; Mikata M; Matsuda H; Ikawa M; Okabe M; Nagasawa S; Matsumoto M; Seya T; Shirakura R Transplant Proc; 1996 Apr; 28(2):1031-3. PubMed ID: 8623217 [No Abstract] [Full Text] [Related]
18. Production of pigs transgenic for human decay accelerating factor. Langford GA; Yannoutsos N; Cozzi E; Lancaster R; Elsome K; Chen P; Richards A; White DJ Transplant Proc; 1994 Jun; 26(3):1400-1. PubMed ID: 7518134 [No Abstract] [Full Text] [Related]
19. Endothelial expression of human decay accelerating factor in transgenic pig tissue: a potential approach for human complement inactivation in discordant xenografts. Rosengard AM; Cary N; Horsley J; Belcher C; Langford G; Cozzi E; Wallwork J; White DJ Transplant Proc; 1995 Feb; 27(1):326-7. PubMed ID: 7533400 [No Abstract] [Full Text] [Related]
20. Inhibition of species-specific complement-mediated cytolysis in xenoendothelial cells transfected with GPI-anchored complement regulatory factor (DAF, HRF20) gene using retroviral vector: comparison between single (DAF or HRF20) and double (DAF and HRF20) transfected xenoendothelial cells. Hayashi S; Isobe K; Emi N; Yokoyama I; Takagi H Transplant Proc; 1994 Jun; 26(3):1243-4. PubMed ID: 7518119 [No Abstract] [Full Text] [Related] [Next] [New Search]